Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Other Non Operating Income (2022 - 2025)

TScan Therapeutics (TCRX) has disclosed Other Non Operating Income for 4 consecutive years, with $881000.0 as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income rose 111.73% to $881000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Dec 2025, up 654.77% year-over-year, with the annual reading at $6.0 million for FY2025, 654.77% up from the prior year.
  • Other Non Operating Income for Q4 2025 was $881000.0 at TScan Therapeutics, down from $1.3 million in the prior quarter.
  • The five-year high for Other Non Operating Income was $2.7 million in Q3 2024, with the low at -$7.5 million in Q4 2024.
  • Average Other Non Operating Income over 4 years is $600750.0, with a median of $1.1 million recorded in 2024.
  • The sharpest move saw Other Non Operating Income soared 2471.43% in 2023, then plummeted 530.56% in 2024.
  • Over 4 years, Other Non Operating Income stood at -$74000.0 in 2022, then soared by 2456.76% to $1.7 million in 2023, then tumbled by 530.56% to -$7.5 million in 2024, then surged by 111.73% to $881000.0 in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at $881000.0, $1.3 million, and $1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.